D-0040-2024 Class III Terminated

Recalled by Imprimis NJOF, LLC — Ledgewood, NJ

FDA drug recall D-0040-2024 was initiated by Imprimis NJOF, LLC on Oct 3, 2023 and is designated Class III. Reason for recall: Subpotent: Failing Test Results for Epinephrine The recall status is terminated (terminated Mar 21, 2025). Affected quantity: 364 bags (1 mL filled in 2 mL glass amber vials; 20 vials shipped in a bag).

Recall details

Product Type
Drugs
Report Date
Oct 11, 2023
Initiation Date
Oct 3, 2023
Termination Date
Mar 21, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
364 bags (1 mL filled in 2 mL glass amber vials; 20 vials shipped in a bag)

Product description

Epinephrine-Lidocaine HCl (0.25mg/mL and 7.5mg/mL) 1mL Single Use Intraocular injection Preservative Free NDC 71384-640-01 Not for resale. Office use only. Lot: 23APR018 Date Compounded: 24APR2023 Expires on: 17APR2024. In case of adverse event contact: www.fda.gov/medwatch or (800)-FDA-1088 Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B, Ledgewood, NJ, 07852 (844) 446-6979

Reason for recall

Subpotent: Failing Test Results for Epinephrine

Distribution pattern

Nationwide

Code information

23APR018

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0040-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0040-2024. Report a data issue: hello@regdatalab.com.